Background: The goal of this study was to assess the clinicopathologic characteristics and prognostic variables in men with breast cancer (BC).
Methods: Clinical features, pathological characteristics, stage at diagnosis, and therapy data were noted. Survival analysis was performed using the log-rank technique and Cox regression model.
Results: Eighty patients were included in the study. In 31% of the individuals, BRCA (BReast CAncer genes 1 and 2) mutations were identified. The estrogen receptor (ER) positivity ratio was 93.6%, whereas the progesterone receptor (PR) positivity ratio was 74.4%. In 16.9% of the cases, HER2 overexpression was found. The median survival time was 120.9 months (70.3-171.5), and the five-year overall survival (OS) ratio was 74.9%. In univariate analysis, BRCA mutation status had no effect on OS (P = 0.50). CA15-3 levels (P = 0.03) at diagnosis and history of smoking (P = 0.03) were significantly linked with OS. However, the multivariate analysis could not confirm these results.
Conclusions: We found that BRCA mutation, body mass index, a history of smoking, and alcohol consumption did not affect the OS in this research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/jcrt.jcrt_243_22 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultrasound-responsive nanoparticles for nitric oxide release to inhibit the growth of breast cancer.
Cancer Cell Int
December 2024
Department of Ultrasound, Chongqing General Hospital, Chongqing University, Chongqing, 401147, China.
Gas therapy represents a promising strategy for cancer treatment, with nitric oxide (NO) therapy showing particular potential in tumor therapy. However, ensuring sufficient production of NO remains a significant challenge. Leveraging ultrasound-responsive nanoparticles to promote the release of NO is an emerging way to solve this challenge.
View Article and Find Full Text PDFMuscle Quality May Improve With Regular Exercise, Improving the Prognosis for Breast Cancer Patients.
Clin Breast Cancer
December 2024
MKA Breast Cancer Clinic, Tepe Prime, Ankara, Turkey. Electronic address:
Targeting CDK2 to circumvent treatment resistance in HR breast cancer.
Trends Mol Med
December 2024
Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address:
Genetic and epigenetic defects of the p53 system have previously been associated with resistance to CDK4/6 inhibitors in women with HR breast cancer. Recent data from Kudo et al. demonstrate that CDK2-targeting agents may offer an effective strategy to circumvent such resistance by enforcing cellular senescence downstream of RBL2 dephosphorylation.
View Article and Find Full Text PDFDabrafenib upregulates hypoglycosylated MUC1 and improves the therapeutic efficacy of Tn-MUC1 CAR-T cells.
Sci Bull (Beijing)
December 2024
Breast Cancer Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. Electronic address:
Computational Pathology Detection of Hypoxia-Induced Morphological Changes in Breast Cancer.
Am J Pathol
December 2024
Department of Computer Science, Faculty of Engineering Sciences, University College London, Gower Street, London, WC1E 6BT, United Kingdom.
Understanding the tumor hypoxic microenvironment is crucial for grasping tumor biology, clinical progression, and treatment responses. This study presents a novel application of AI in computational histopathology to evaluate hypoxia in breast cancer. Weakly Supervised Deep Learning (WSDL) models can accurately detect morphological changes associated with hypoxia in routine Hematoxylin and Eosin (H&E) whole slide images (WSI).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!